The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 17, 2017
Filed:
Aug. 13, 2013
Helmholtz Zentrum Munchen—deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh), Neuherberg, DE;
Deutsche Diabetes-forschungsgesellschaft E.v.—trager Des Deutschen Diabetes-zentrums Dusseldorf, Dusseldorf, DE;
Eberhard Karls Universitat Tubingen, Medizinische Fakultat, Tubingen, DE;
Wolfgang Rathmann, Essen, DE;
Christian Herder, Dusseldorf, DE;
Thomas Illig, Hannover, DE;
Jerzy Adamski, Munich, DE;
Rui Wang-Sattler, Munich, DE;
Zhongao Yu, Munich, DE;
H.-Erich Wichmann, Neuherberg, DE;
Hans-Ulrich Haring, Stuttgart, DE;
Michael Roden, Vienna, AT;
Annette Peters, Munich, DE;
Christine Meisinger, Aichach, DE;
Martin Hrabe De Angelis, Starnberg, DE;
Thomas Meitinger, Munich, DE;
Abstract
The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.